The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae

Doi, Asako; Shimada, Toru; Harada, Sohei; Iwata, Kentaro; Kamiya, Toru

doi:10.1016/j.ijid.2012.09.010

Cited by 67 publications

(46 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To date, 5 reports have evaluated the efficacy of cephamycins for the treatment of infections ESBL-producing members of the Enterobacteriaceae (8,(19)(20)(21)(22). All of these single-center retrospective studies included a small number of patients and a control group comprised of patients receiving carbapenem.…”

Section: Discussionmentioning

confidence: 99%

Multicenter Retrospective Study of Cefmetazole and Flomoxef for Treatment of Extended-Spectrum-β-Lactamase-Producing Escherichia coli Bacteremia

Matsumura

Yamamoto

Nagao

et al. 2015

Antimicrob Agents Chemother

View full text Add to dashboard Cite

. Adult patients treated for E. coli bacteremia in four hospitals were retrospectively evaluated. The 30-day mortality rates in patients belonging to the ESBL-CF, ESBL-carbapenem, and non-ESBL-CF groups were compared as 2 (empirical and definitive therapy) cohorts. The adjusted hazard ratios (aHRs) for mortality were calculated using Cox regression models with weighting according to the inverse probability of propensity scores for receiving CF or carbapenem treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Multicenter Retrospective Study of Cefmetazole and Flomoxef for Treatment of Extended-Spectrum-β-Lactamase-Producing Escherichia coli Bacteremia

Matsumura

Yamamoto

Nagao

et al. 2015

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Data on the effectiveness of treatment using cephamycins and oxacephems for the ESBL-producing organisms are scarce (31,32), and further studies regarding the optimal clinical uses of these drugs for the treatment of ESBL-producing E. coli are warranted.…”

Section: Discussionmentioning

confidence: 99%

Clinical Epidemiology and Molecular Analysis of Extended-Spectrum-β-Lactamase-Producing Escherichia coli in Nepal: Characteristics of Sequence Types 131 and 648

Sherchan

Hayakawa

Miyoshi‐Akiyama

et al. 2015

Antimicrob Agents Chemother

View full text Add to dashboard Cite

f Recently, CTX-M-type extended-spectrum-␤-lactamase (ESBL)-producing Escherichia coli strains have emerged worldwide. In particular, E. coli with O antigen type 25 (O25) and sequence type 131 (ST131), which is often associated with the CTX-M-15 ESBL, has been increasingly reported globally; however, epidemiology reports on ESBL-producing E. coli in Asia are limited. Patients with clinical isolates of ESBL-producing E. coli in the Tribhuvan University teaching hospital in Kathmandu, Nepal, were included in this study. Whole-genome sequencing of the isolates was conducted to analyze multilocus sequence types, phylotypes, virulence genotypes, O25b-ST131 clones, and distribution of acquired drug resistance genes. During the study period, 105 patients with ESBL-producing E. coli isolation were identified, and the majority (90%) of these isolates were CTX-M-15 positive. The most dominant ST was ST131 (n ‫؍‬ 54; 51.4%), followed by ST648 (n ‫؍‬ 15; 14.3%). All ST131 isolates were identified as O25b-ST131 clones, subclone H30-Rx. Three ST groups (ST131, ST648, and non-ST131/648) were compared in further analyses. ST648 isolates had a proportionally higher resistance to non-␤-lactam antibiotics and featured drug-resistant genes more frequently than ST131 or non-ST131/648 isolates. ST131 possessed the most virulence genes, followed by ST648. The clinical characteristics were similar among groups. More than 38% of ESBL-producing E. coli isolates were from the outpatient clinic, and pregnant patients comprised 24% of ESBL-producing E. coli cases. We revealed that the high resistance of ESBL-producing E. coli to multiple classes of antibiotics in Nepal is driven mainly by CTX-M-producing ST131 and ST648. Their immense prevalence in the communities is a matter of great concern. E scherichia coli is a part of the normal human and animal gastrointestinal flora; it is the most common cause of urinary tract infections and also causes various other infectious conditions, such as intra-abdominal infections, neonatal meningitis, and septicemia (1-3).Recently, extended-spectrum-beta-lactamase (ESBL) producing E. coli strains, particularly strains producing CTX-M-type ESBLs, have emerged worldwide (4). In particular, E. coli with O antigen type 25 (O25) and sequence type 131 (ST131) is often associated with the CTX-M-15 ESBL and has been increasingly reported globally. These bacteria are resistant to classes of antibiotics distinct from ␤-lactams, such as fluoroquinolones and trimethoprim-sulfamethoxazole (5, 6). Epidemiology reports on ESBLproducing E. coli in Asia are limited to date. To the best of our knowledge, there has been no report on the prevalence of pandemic ESBL-producing E. coli ST131, or other potentially dominant ESBL-producing E. coli STs, or clinical and microbiological information pertaining to their isolation in Nepal. Nepal is located in south Asia and adjacent to India, where a high proportion of resistant Gram-negative bacteria has been reported (7); understanding the epidemiology of ESBL-producing E. coli in t...

show abstract

“…Unfortunately, clinical data evaluating cephamycins for ESBL infections are scarce, and data comparing the relative efficacy of the various cephamycins are virtually nonexistent. Existing observational studies comparing cephamycins and carbapenems are plagued by the inherent limitations of observational studies-most notably confounding by indication-as well as small sample sizes (Table 2) [15][16][17][18][19][20]. Only 1 of these studies showed improved outcomes among ESBL-infected patients treated with carbapenems compared with cephamycins, while the others could not detect differences [18] (Table 3).…”

Section: Cephamycinsmentioning

confidence: 99%

The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections

Tamma¹,

Rodríguez‐Baño

2017

Clinical Infectious Diseases

151

125

View full text Add to dashboard Cite

The continued rise in infections caused by extended-spectrum β-lactamase (ESBL)-producing pathogens is recognized globally as one of the most pressing concerns facing the healthcare community. Carbapenems are widely regarded as the antibiotics of choice for the treatment of ESBL-producing infections, even when in vitro activity to other β-lactams has been demonstrated. However, indiscriminant carbapenem use is not without consequence, and carbapenem overuse has contributed to the emergence of carbapenem-resistant Enterobacteriaceae. The use of non-carbapenem β-lactams for the treatment of ESBL infections has yielded conflicting results. In this review, we discuss the available data for the use of cephamycins, cefepime, piperacillin-tazobactam, ceftolozane-tazobactam, and ceftazidime-avibactam for the treatment of ESBL infections.

show abstract

The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae

Abstract: Cefmetazole may be a useful option for the treatment of UTIs caused by ESBL-producing organisms. Prospective and larger sized studies are needed to confirm our findings.

Cited by 67 publications

References 29 publications

Multicenter Retrospective Study of Cefmetazole and Flomoxef for Treatment of Extended-Spectrum-β-Lactamase-Producing Escherichia coli Bacteremia

Multicenter Retrospective Study of Cefmetazole and Flomoxef for Treatment of Extended-Spectrum-β-Lactamase-Producing Escherichia coli Bacteremia

Clinical Epidemiology and Molecular Analysis of Extended-Spectrum-β-Lactamase-Producing Escherichia coli in Nepal: Characteristics of Sequence Types 131 and 648

The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections

Contact Info

Product

Resources

About